I am an investor

Read more

I want to know more about
Cantargia's research

Read more

I want to know more about
Cantargia as a company

Read more

Antibody-based therapies targeting IL1RAP

For treatment of cancer and autoimmune and inflammatory diseases

Our projects

Cantargia presents at Redeye Fight Cancer

To the presentation

Cantargia presents at BioStock Life Science Fall Summit 2022

To the presentation

”Cantargia is in a strong position with many upcoming milestones in our two development programs. The presentations at the ASCO conference during 2022 generated a lot of attention, and we have very exciting times ahead of us.”


Göran Forsberg
CEO Cantargia